Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | NPY4R | P50391 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 4/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.35 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.35 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869032 | 1.00 | NPY1R (0.51) | NPY1RNPY2RNPY4RNPY5RABL1 | |
| SCHEMBL1869027 | 1.00 | NPY1R (0.51) | NPY1RNPY2RNPY4RNPY5RABL1 | |
| SCHEMBL1870265 | 0.81 | CHRNB2 (0.42) | NPY1RNPY2RNPY4RNPY5RABL1 | |
| SCHEMBL1870263 | 0.81 | CHRNB2 (0.42) | NPY1RNPY2RNPY4RNPY5RABL1 | |
| SCHEMBL1870261 | 0.81 | CHRNB2 (0.42) | NPY1RNPY2RNPY4RNPY5RABL1 | |
| SCHEMBL20022643 | 0.79 | NPY1R (0.73) | NPY1RNPY2RNPY4RNPY5RABL1 | |
| SCHEMBL1496528 | 0.78 | NPY1R (0.63) | NPY1RNPY2RNPY4RNPY5RABL1 | |
| SCHEMBL1872677 | 0.78 | NPY1R (0.63) | NPY1RNPY2RNPY4RNPY5RABL1 | |
| SCHEMBL1872678 | 0.78 | NPY1R (0.63) | NPY1RNPY2RNPY4RNPY5RABL1 | |
| SCHEMBL2656329 | 0.78 | CHRNB2 (0.47) | ABL1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051917-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC (US) | 2024-02-15 | — | — | US | disclosed |
| US-20190100491-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2019-04-04 | — | — | US | disclosed |
| US-20170247360-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC. | 2017-08-31 | — | — | US | disclosed |
| US-20160272625-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20140323502-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC. | 2014-10-30 | — | — | US | disclosed |
| EP-2445883-B1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2012-12-20 | — | — | US | disclosed |
| US-8278457-B2 | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2445883-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | PFIZER INC. | 2011-05-05 | — | — | US | disclosed |
| WO-2010150192-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | NPY1R 1701/4885NPY2R 1635/4885NPY4R 1687/4885 |
| US-20240051917-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | NPY1R 1701/4885NPY2R 1635/4885NPY4R 1687/4885 |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | NPY1R 1701/4885NPY2R 1635/4885NPY4R 1687/4885 |
| US-20140323502-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | NPY1R 1701/4885NPY2R 1635/4885NPY4R 1687/4885 |
| US-20160272625-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | NPY1R 1701/4885NPY2R 1635/4885NPY4R 1687/4885 |
| US-20170247360-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | NPY1R 1701/4885NPY2R 1635/4885NPY4R 1687/4885 |
| US-20190100491-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | NPY1R 1701/4885NPY2R 1635/4885NPY4R 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.